Welcome to our dedicated page for Kodiak Sciences SEC filings (Ticker: KOD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Kodiak Sciences Inc. (Nasdaq: KOD) SEC filings, offering insight into how the precommercial retina-focused biotechnology company reports its activities to regulators. Kodiak Sciences develops biologic therapeutics for retinal vascular diseases and macular edema secondary to inflammation (MESI), and its filings reflect the progress and funding of these programs.
Investors can review Form 8-K current reports where Kodiak discloses material events, such as quarterly financial results and business highlights, or the terms and completion of public offerings of common stock. For example, a December 18, 2025 Form 8-K describes the underwriting agreement and closing of an 8,000,000-share public offering that generated gross proceeds of approximately $184 million before expenses.
Through its shelf registration statement on Form S-3 and related prospectus supplements, Kodiak outlines how it may issue securities to finance its late-stage clinical programs, including Phase 3 studies like GLOW2, DAYBREAK, PEAK and PINNACLE. Additional filings, such as quarterly and annual reports when available, typically provide more detail on research and development expenses, cash position and the status of clinical trials for tarcocimab, KSI-501 and KSI-101.
On Stock Titan, users can view Kodiak’s latest SEC submissions as they are posted to EDGAR and use AI-powered tools to summarize complex documents. These tools can help explain offering terms, highlight key clinical and financial disclosures, and surface information on topics such as capital raising, research spending and trial milestones relevant to KOD.
Kodak Sciences Inc. (KOD) remains a precommercial retina-focused biotech, reporting a net loss of $58.2 million for the quarter ended March 31, 2026, on operating expenses of $59.8 million. Research and development was $48.5 million, driven by late-stage programs Zenkuda (tarcocimab), KSI-501 and KSI-101, while general and administrative costs fell to $11.2 million as prior lease impairment and higher stock-based compensation rolled off.
Cash and cash equivalents were $169.5 million, with total assets of $306.0 million and a $100.0 million liability related to the sale of future royalties. Operating cash burn was $40.0 million in the quarter. The company has an accumulated deficit of $1.62 billion and discloses that its financial condition raises substantial doubt about its ability to continue as a going concern, even as it plans additional financing to support Phase 3 trials and prospective biologics license applications in diabetic retinopathy, retinal vein occlusion, wet AMD and macular edema secondary to inflammation.
Kodiak Sciences reported first quarter 2026 results and highlighted major progress in its retina drug pipeline. In the GLOW2 Phase 3 study in diabetic retinopathy, Zenkuda achieved a ≥2-step DRSS improvement in 62.5% of treated patients versus 3.3% on sham and cut sight‑threatening complications to 2.4% versus 15.8% on sham, supporting a multi‑indication BLA‑ready profile.
The company expects topline DAYBREAK Phase 3 wet AMD data for Zenkuda and KSI‑501 in Q3 2026, PEAK MESI data in Q4 2026, and PINNACLE MESI data in Q2 2027. Kodiak ended the quarter with $169.5 million in cash and cash equivalents and recorded a net loss of $58.2 million (basic and diluted loss of $0.94 per share), driven by $48.5 million in R&D and $11.2 million in G&A expenses. Management believes this cash will fund operations into 2027.
Kodiak Sciences Inc reports that BlackRock, Inc. beneficially owned 3,273,386 shares of Common Stock, representing 5.3% of the class as of 03/31/2026. The filing shows BlackRock has sole voting power for 3,221,479 shares and sole dispositive power for 3,273,386 shares. The schedule is signed by a BlackRock managing director on 04/27/2026.
Kodiak Sciences Inc. is soliciting proxies for its 2026 Annual Meeting, a virtual-only event on June 2, 2026. Stockholders of record on April 6, 2026 will vote on electing three Class II directors, an advisory say-on-pay resolution, and ratifying PricewaterhouseCoopers LLP as auditor.
The proxy describes a staggered, largely independent seven-member board, with directors and related options owning 29,786,724 shares, or 43% of common stock as of March 31, 2026. Executive pay is heavily performance-based: in 2025 about 68% of CEO and 65% of CFO compensation was at risk, and both received bonuses equal to 150% of target after exceeding clinical, regulatory, pipeline and financing goals. Kodiak outlines plans to file a Biologics License Application in diabetic retinopathy, retinal vein occlusion and wet AMD in 2026 and highlights multiple Phase 3 programs and an AI-enabled retinal imaging headset.
Kodiak Sciences Inc. Chief Financial Officer John A. Borgeson exercised stock options to acquire 28,614 shares of common stock at an exercise price of $1.04 per share. Following the transaction, he directly owns 211,930 common shares and holds options for 30,000 additional shares. The options exercised were already fully vested, indicating this was a routine compensation-related exercise rather than an open-market purchase or sale.
Kodiak Sciences Inc. Chief Financial Officer John A. Borgeson reported an exercise-and-sell transaction involving company stock. On April 2, 2026, he exercised stock options to acquire 30,000 shares of Common Stock at an exercise price of $1.04 per share. The option was fully vested and scheduled to expire on June 22, 2026.
On the same date, he sold a total of 30,000 Common shares in multiple open-market transactions at weighted-average prices of $39.14, $40.29, $40.88, and $41.77 per share. These sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025. After these transactions, Borgeson directly holds 183,316 shares of Kodiak Sciences Common Stock.
Kodiak Sciences Inc. was reported as having 609,806 shares beneficially owned by Point72-affiliated reporting persons. The filing, a Schedule 13G, shows the holders — Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen — have a 1.0% ownership stake as of the close of business on April 1, 2026.
The statement notes shared voting and dispositive power of 609,806 shares and that the reporting persons directly own no shares; a Joint Filing Agreement is attached as Exhibit 99.1.
Kodiak Sciences Inc. files its annual report describing an advanced retinal disease drug pipeline and significant business risks. The company focuses on its Antibody Biopolymer Conjugate platform and three late-stage candidates: Zenkuda (tarcocimab), KSI-501 and KSI-101 for diabetic eye disease, wet AMD, retinal vein occlusion and inflammation-driven macular edema.
Multiple Phase 3 programs, including GLOW1, GLOW2, BEACON and DAYLIGHT, met primary endpoints, while DAYBREAK, PEAK and PINNACLE remain ongoing with topline data expected between 3Q 2026 and 2Q 2027. Kodiak also discloses substantial doubt about its ability to continue as a going concern and highlights dependence on additional financing, regulatory approvals and successful commercialization.